Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Seer (Nasdaq: SEER) reported first quarter 2026 revenue of $2.8 million, down 34% year-over-year, with gross margin of 35% and net loss of $16.8 million. Operating expenses fell 20% to $18.2 million. The company ended the quarter with about $220 million in cash and investments and reaffirmed 2026 revenue guidance of $16–$18 million.
Seer highlighted a major collaboration in Singapore covering 10,000 samples, a doubling of independent publications to 84, a U.S. patent office decision reinforcing its IP position, and repurchase of about 1.5 million Class A shares.
Summary not available.
Seer (Nasdaq: SEER) appointed Anthony Bazarko as Chief Commercial Officer on May 4, 2026. Bazarko brings more than two decades of commercial leadership and will lead Sales, Marketing, and Customer Experience to accelerate adoption of the Proteograph® Product Suite.
Bazarko served as President and CEO of Biologos (2022–2025), was CCO at Specific Diagnostics, and held senior commercial roles at Danaher and Roche.
Seer products are for research use only and are not diagnostic.
Seer (Nasdaq: SEER) will report first-quarter 2026 financial results on May 13, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be on the Investor section of Seer's website and an archived replay will follow.
Summary not available.
Seer (Nasdaq: SEER) announced its Board unanimously rejected a revised unsolicited proposal from the Radoff-JEC Group received April 24, 2026, offering $2.35 per share in cash plus a contingent value right. The Board concluded the proposal materially undervalues Seer versus cash, investments and platform value.
The Board highlighted Seer’s Proteograph product suite, selection for Singapore’s SGK100 study, more than 80 peer‑reviewed publications, and 240 patents and applications (82 issued), and said stockholders need take no action at this time.
Summary not available.
Seer (Nasdaq: SEER) confirmed receipt of a non-binding, unsolicited proposal from the Radoff-JEC Group to acquire all Class A shares for $2.25 per share in cash plus a contingent value right.
The group also nominated three director candidates for Seer’s 2026 Annual Meeting. The Board, with financial and legal advisors, will review the Proposal and nominations; no stockholder action is required at this time.
Summary not available.